FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2317730906> ?p ?o ?g. }

• W2317730906 endingPage "313" @default.
• W2317730906 startingPage "313.1" @default.
• W2317730906 abstract "<h3>Background</h3> Etiologies of non infectious inflammatory uveitis are multiple. Their prognosis can be severe and may lead to blindness. Anti-TNF alpha are used for several years in refractory inflammatory uveitis but few data on large studies have been reported. <h3>Objectives</h3> The aim of this study is to report on the efficacy and the safety of anti-TNF alpha in inflammatory uveitis. <h3>Methods</h3> We performed a retrospective multicenter study of main characteristics and outcomes of 162 patients with inflammatory uveitis treated with anti-TNF alpha. <h3>Results</h3> The median of age was 30 years [19-40] and with 59% of women. Uveitis were mainly bilateral (82%) and chronic (87%). Panuveitis, macular oedema and retinal vasculitis were observed in 62, 54 and 35% of cases, respectively. Main etiologies of uveitis included juvenile idiopathic arthritis (25%), Behçet9s disease (24%), spondylarthropathies (12%), and sarcoidosis (6%). Patients were treated by infliximab in 58%, adalimumab in 39.5% or etanercept in 2.5%. The median of follow up was 27 months [8-55]. Ninety three percent of patients were complete or partial responders to anti-TNF alpha therapy. No significant difference was found relative to efficacy between infliximab and adalimumab. Anti-TNF alpha had a significant corticosteroid sparing effect (daily prednisolone dose of 20mg at time of introduction of anti-TNF alpha vs 10mg and 5mg at 6 and 12 months, respectively; p<0,0001). The median time for clinical improvement was 67 days [43-103]. Adverse events were reported in 27% of patients, mainly with infliximab. They included mainly infections (8%) and hypersensitivity reactions (7%). Serious side effects were reported in 10% of cases and required treatment interruption in all cases. <h3>Conclusions</h3> These preliminary results showed that TNF alpha inhibitors are highly efficient in severe and refractory non infectious inflammatory uveitis. Infliximab and adalimumab had the same efficacy profile but infliximab was associated with more frequent and more serious side effects. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6013" @default.
• W2317730906 created "2016-06-24" @default.
• W2317730906 creator A5002774188 @default.
• W2317730906 creator A5026495111 @default.
• W2317730906 creator A5030711598 @default.
• W2317730906 creator A5031821767 @default.
• W2317730906 creator A5032588310 @default.
• W2317730906 creator A5037078532 @default.
• W2317730906 creator A5041077575 @default.
• W2317730906 creator A5050352531 @default.
• W2317730906 creator A5053823490 @default.
• W2317730906 creator A5063812606 @default.
• W2317730906 creator A5064732325 @default.
• W2317730906 creator A5079064792 @default.
• W2317730906 creator A5082855830 @default.
• W2317730906 creator A5085598342 @default.
• W2317730906 creator A5085912537 @default.
• W2317730906 creator A5086216178 @default.
• W2317730906 creator A5087482219 @default.
• W2317730906 creator A5087741774 @default.
• W2317730906 creator A5090001534 @default.
• W2317730906 creator A5090986945 @default.
• W2317730906 date "2014-06-01" @default.
• W2317730906 modified "2023-09-27" @default.
• W2317730906 title "THU0379 Efficacy and Safety of Anti-TNF Alpha in NON Infectious Inflammatory Uveitis: Preliminary Results of A French Multicenter Registry of 162 Patients" @default.
• W2317730906 doi "https://doi.org/10.1136/annrheumdis-2014-eular.6013" @default.
• W2317730906 hasPublicationYear "2014" @default.
• W2317730906 type Work @default.
• W2317730906 sameAs 2317730906 @default.
• W2317730906 citedByCount "0" @default.
• W2317730906 crossrefType "journal-article" @default.
• W2317730906 hasAuthorship W2317730906A5002774188 @default.
• W2317730906 hasAuthorship W2317730906A5026495111 @default.
• W2317730906 hasAuthorship W2317730906A5030711598 @default.
• W2317730906 hasAuthorship W2317730906A5031821767 @default.
• W2317730906 hasAuthorship W2317730906A5032588310 @default.
• W2317730906 hasAuthorship W2317730906A5037078532 @default.
• W2317730906 hasAuthorship W2317730906A5041077575 @default.
• W2317730906 hasAuthorship W2317730906A5050352531 @default.
• W2317730906 hasAuthorship W2317730906A5053823490 @default.
• W2317730906 hasAuthorship W2317730906A5063812606 @default.
• W2317730906 hasAuthorship W2317730906A5064732325 @default.
• W2317730906 hasAuthorship W2317730906A5079064792 @default.
• W2317730906 hasAuthorship W2317730906A5082855830 @default.
• W2317730906 hasAuthorship W2317730906A5085598342 @default.
• W2317730906 hasAuthorship W2317730906A5085912537 @default.
• W2317730906 hasAuthorship W2317730906A5086216178 @default.
• W2317730906 hasAuthorship W2317730906A5087482219 @default.
• W2317730906 hasAuthorship W2317730906A5087741774 @default.
• W2317730906 hasAuthorship W2317730906A5090001534 @default.
• W2317730906 hasAuthorship W2317730906A5090986945 @default.
• W2317730906 hasConcept C126322002 @default.
• W2317730906 hasConcept C141071460 @default.
• W2317730906 hasConcept C17991360 @default.
• W2317730906 hasConcept C197934379 @default.
• W2317730906 hasConcept C203014093 @default.
• W2317730906 hasConcept C2776015282 @default.
• W2317730906 hasConcept C2776194053 @default.
• W2317730906 hasConcept C2776715498 @default.
• W2317730906 hasConcept C2777138892 @default.
• W2317730906 hasConcept C2777226972 @default.
• W2317730906 hasConcept C2778257484 @default.
• W2317730906 hasConcept C2778328719 @default.
• W2317730906 hasConcept C2779134260 @default.
• W2317730906 hasConcept C2780132546 @default.
• W2317730906 hasConcept C2780347916 @default.
• W2317730906 hasConcept C2781301800 @default.
• W2317730906 hasConcept C71924100 @default.
• W2317730906 hasConcept C90924648 @default.
• W2317730906 hasConceptScore W2317730906C126322002 @default.
• W2317730906 hasConceptScore W2317730906C141071460 @default.
• W2317730906 hasConceptScore W2317730906C17991360 @default.
• W2317730906 hasConceptScore W2317730906C197934379 @default.
• W2317730906 hasConceptScore W2317730906C203014093 @default.
• W2317730906 hasConceptScore W2317730906C2776015282 @default.
• W2317730906 hasConceptScore W2317730906C2776194053 @default.
• W2317730906 hasConceptScore W2317730906C2776715498 @default.
• W2317730906 hasConceptScore W2317730906C2777138892 @default.
• W2317730906 hasConceptScore W2317730906C2777226972 @default.
• W2317730906 hasConceptScore W2317730906C2778257484 @default.
• W2317730906 hasConceptScore W2317730906C2778328719 @default.
• W2317730906 hasConceptScore W2317730906C2779134260 @default.
• W2317730906 hasConceptScore W2317730906C2780132546 @default.
• W2317730906 hasConceptScore W2317730906C2780347916 @default.
• W2317730906 hasConceptScore W2317730906C2781301800 @default.
• W2317730906 hasConceptScore W2317730906C71924100 @default.
• W2317730906 hasConceptScore W2317730906C90924648 @default.
• W2317730906 hasIssue "Suppl 2" @default.
• W2317730906 hasLocation W23177309061 @default.
• W2317730906 hasOpenAccess W2317730906 @default.
• W2317730906 hasPrimaryLocation W23177309061 @default.
• W2317730906 hasRelatedWork W2054650264 @default.
• W2317730906 hasRelatedWork W2078470312 @default.
• W2317730906 hasRelatedWork W2111615368 @default.
• W2317730906 hasRelatedWork W2550458380 @default.
• W2317730906 hasRelatedWork W3033493152 @default.
• W2317730906 hasRelatedWork W3040052008 @default.
• W2317730906 hasRelatedWork W3129801091 @default.

• next